Bio-Techne Announces Release of GMP TcBuster Non-Viral Genome Engineering System

Core Insights - Bio-Techne Corporation has officially released GMP Transposase mRNA for the TcBuster™ non-viral genome engineering system, aimed at supporting the development of immune cell- and stem cell-based therapies [1][2] Product Overview - The TcBuster System is designed for introducing large genetic modifications in various cell types, facilitating gene-edited cell therapies such as CAR-T or TCR generation [2][4] - The new GMP transposase enhances the TcBuster system, allowing for the simultaneous delivery of multiple genes while maintaining high editing efficiency and a safer insertional profile [3][4] Competitive Advantages - The non-viral TcBuster system offers significant benefits over traditional lentivirus-based methods, including reduced time to market and lower costs due to the elimination of viral clearance processes [3][4] - Bio-Techne has established a reliable supply chain for both RUO and GMP grade reagents, supporting scalable manufacturing from research to clinical and commercial stages [3] Market Applications - The TcBuster system is compatible with various cell types, including immune and stem cells, and can be utilized for applications such as autologous CAR-T or TCR manufacturing, allogeneic NK therapies, and engineering bioprocessing cell lines for therapeutic biologics production [4] Company Background - Bio-Techne Corporation is a global life sciences company that generated approximately $1.2 billion in net sales in fiscal 2024 and employs around 3,100 people worldwide [6]